Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy of dydrogesterone 30 mg compared to micronized vaginal
progesterone 800 mg daily for luteal phase support in hormone replacement therapy frozen
embryo transfer cycles, as confirmed by visualization of fetal heart activity by pelvic
ultrasound assessment of ongoing pregnancy at 12 weeks of gestation.